Hepatitis B: seguimientos serológico y virológico de la respuesta y la resistencia al tratamiento antiviral

Rodríguez-Frías, F.; Jardí, R.

Información del artículo

Bibliografía

Descargar PDF

Estadísticas

El Texto completo está disponible en PDF

Bibliografía

[1]

Lavanchy D..

Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures..

J Viral Hepat. , 11 (2004), pp. 97-107

Medline

[2]

Iloeje UH, Yang HI, Su J, Jen CL, You SL, Cen CJ..

Predicting cirrhosis risk based on he level of circulating hepatitis B viral load..

Gastroenterology. , 130 (2006), pp. 678-86

http://dx.doi.org/10.1053/j.gastro.2005.11.016 | Medline

[3]

Seeger C, Mason WS..

Hepatitis B virus biology..

Microbiol Mol Biol Rev. , 64 (2000), pp. 51-68

Medline

[4]

Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al..

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis..

J Virol. , 75 (2001), pp. 311-22

http://dx.doi.org/10.1128/JVI.75.1.311-322.2001 | Medline

[5]

Wai CT, Fontana RJ..

Clinical significance of hepatitis B virus genotypes, variants and mutants..

Clin Liver Dis. , 8 (2004), pp. 321-52

Medline

[6]

Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, et al..

Hepatitis B virus infection: Precore mutants and its relation to viral genotypes and core mutations..

Hepatology. , 22 (1995), pp. 1641-7

Medline

[7]

Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J..

Influence of hepatitis B virus genotypes on the long-term outcome of chronic B hepatitis in western patients..

Gastroenterology. , 123 (2002), pp. 1848-56

http://dx.doi.org/10.1053/gast.2002.37041 | Medline

[8]

Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al..

Virologic response and resistance to adefovir in patients with chronic hepatitis B..

J Hepatol. , 44 (2006), pp. 283-90

http://dx.doi.org/10.1016/j.jhep.2005.10.018 | Medline

[9]

Janssen HLA, Van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al (for the HBV 99 -01 Study Group)..

Pegylated interferon alfa 2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial..

Lancet. , 365 (2005), pp. 123-9

http://dx.doi.org/10.1016/S0140-6736(05)17701-0 | Medline

[10]

Perrillo RP..

Current treatment of chronic hepatitis B: benefits and limitations..

Seminars Liv Dis. , 25 Suppl 2 (2005), pp. 20-8

[11]

Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al..

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients..

J Hepatol. , 47 (2007), pp. 366-72

http://dx.doi.org/10.1016/j.jhep.2007.04.011 | Medline

[12]

Zoulim F..

New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA..

J Hepatol. , 42 (2005), pp. 302-8

http://dx.doi.org/10.1016/j.jhep.2004.12.015 | Medline

[13]

Revilla J, Pons F, Calleja JL..

Resistencias al virus B y terapias combinadas..

Clin Gastroentero Hepatol. , 7 (2007), pp. 7-24

[14]

Bruguera M, Bañares R, Córdoba J, Jardí R, González-Lahoz J, Ladero JM, et al..

Documento consenso de la AEEH sobre el tratamiento de las infecciones por los virus de las hepatitis B y C..

Gastroenterol Hepatol. , 29 Suppl 2 (2006), pp. S216-S230

http://dx.doi.org/10.1016/j.gastrohep.2012.01.004 | Medline

[15]

Hadziyannis S, Tassopoulos N, Chag TT, Heathcote J, Kitis G, Rizzetto M, et al..

Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg negative chronic hepatitis B: results after 5 years of therapy..

Hepatology. , 42 (2005), pp. 754A

[16]

Lok AS, McMahon BJ..

Chronic hepatitis B..

Hepatology. , 45 (2007), pp. 507-39

http://dx.doi.org/10.1002/hep.21513 | Medline

[17]

Hoofnagle J, Doo E, Liang T, Fleischer R, Lok AS..

Management of hepatitis B: Summary of a clinical research workshop..

Hepatology. , 45 (2007), pp. 1057-75

[18]

Lok AS..

Navigating the maze of hepatitis B virus treatments..

Gastroenterology. , 132 (2007), pp. 1586-94

http://dx.doi.org/10.1053/j.gastro.2007.02.040 | Medline

[19]

Hadziyannis S, Tassopoulos N, Heathcote J, Chag TT, Kitis G, Rizzetto M, et al, Adefovir Dipivoxil 438 Study Group..

Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B..

N Engl J Med. , 352 (2005), pp. 2673-81

http://dx.doi.org/10.1056/NEJMoa042957 | Medline

[20]

Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M Pawlostsky J..

Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendatios for management..

Hepatology. , 46 (2007), pp. 254-65

http://dx.doi.org/10.1002/hep.21698 | Medline

[21]

Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Multimer D, et al..

Management of antiviral resistance in patients with chronic hepatitis B..

Antivir Ther. , 9 (2004), pp. 679-93

Medline

[22]

Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V..

Mutations affecting the replication capacity of the hepatitis B virus..

J Viral Hepat. , 13 (2006), pp. 427-34

http://dx.doi.org/10.1111/j.1365-2893.2005.00713.x | Medline

[23]

Baumert TF, Thimme R, Von Weizsäker..

Pathogenesis of hepatitis B virfus infection..

World J Gastroenterol. , 13 (2007), pp. 82-90

Medline

[24]

Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al..

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy..

Hepatology. , 33 (2001), pp. 1527-32

http://dx.doi.org/10.1053/jhep.2001.25084 | Medline

[25]

Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al..

Long-term safety of lamivudine treatment in patients with chronic hepatitis B..

Gastroenterology. , 125 (2003), pp. 1714-22

Medline

[26]

Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, et al..

The clinical impact of early detection of the YMDD mutant on the outcomes of long term lamivudine therapy in patients with chronic hepatitis B..

Antivir Ther. , 11 (2006), pp. 447-55

Medline

[27]

Multimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al..

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient..

Gut. , 46 (2000), pp. 107-13

Medline

[28]

Suárez-Garcia E..

Monitorización del tratamiento y definición de la respuesta..

Gastroenterol Hepatol. , 29 Suppl 2 (2006), pp. 23-6

http://dx.doi.org/10.1016/j.gastrohep.2012.01.004 | Medline

[29]

Zoulim F..

Virology of Hepatitis B: Capitulo 5 Management of antiviral resistance in clinical practice..

, 2004. p. 61-71 (Paris: Elsevier SAS),

[30]

Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al..

Persistence of cccDNA during the natural history of chronic hepatiti B and decline during adefovir dipivoxil therapy..

Gastroenterology. , 126 (2004), pp. 1750-8

Medline

[31]

Funk ML, Rosenberg DM, Lok ASF..

World-wide epidemiology of HBeAg negative chronic hepatitis B and associated precore and core promoter variants..

J Viral Hepat. , 9 (2002), pp. 52-61

Medline

[32]

Valsamakis A..

Molecular testing in the diagnosis and management of chronic hepatitis B..

Clin Microbiol Rev. , 20 (2007), pp. 426-39

http://dx.doi.org/10.1128/CMR.00009-07 | Medline

[33]

Osborn M, Lok AS..

Antiviral options for the treatment of chronic hepatitis B..

J Antimic Chemother. , 57 (2006), pp. 1030-4

[34]

Mommeja-Marin H, Mondou E, Blum R, Rousseau F..

Serum HBV DNA as a markser of efficacy during therapy for chronic HBV infection: analysis and review of the literature..

Hepatology. , 37 (2003), pp. 1309-19

http://dx.doi.org/10.1053/jhep.2003.50208 | Medline

[35]

Keeffe EB, Dieterich DT, Han SHB, Jacobson IM, Martin P, Schiff ER, et al..

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update..

Clin Gastroenterol. , 4 (2006), pp. 936-62

[36]

European Association for the Study of the Liver..

Proceeding of the European Association for the Study of the Liver (EASL).International Consensus Conference on Hepatitis B. September 14-16, 2002. Geneva, Switzerland..

J Hepatol. , 39 Suppl 1 (2003), pp. S1-S235

http://dx.doi.org/10.1016/j.jhep.2012.09.014 | Medline

[37]

Liaw YF, Leung N, Guan R, Lu K, Merican I, Mc Caughan G, et al..

Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2005 update..

Liver Int. , 25 (2005), pp. 472-89

http://dx.doi.org/10.1111/j.1478-3231.2005.01134.x | Medline

[38]

Pawlotsky JM..

Hepatitis B virus (HBV) DNA assays (methods AN practical use) and viral kinetics..

J Hepatol. , 39 (2003), pp. S31-S35

Medline

[39]

Martinot-Peignoux M, Boyer N, Colombat M, Akremi B, Pham BM, Ollivier S, et al..

Serum hepatitis B DNA levels and liver histology in inactive HBsAg carriers..

J Hepatol. , 36 (2002), pp. 543-6

Medline

[40]

Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ..

Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection..

Am J Gastroenterol. , 98 (2003), pp. 2261-7

http://dx.doi.org/10.1111/j.1572-0241.2003.07715.x | Medline

[41]

Van de Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HL, Schalm SW, et al..

Quantitative HBV DNA levels as an early predictor of non response in chronic HBe antigen positive hepatitis B patients treated with interferon alfa..

J Viral Hepat. , 13 (2006), pp. 96-103

http://dx.doi.org/10.1111/j.1365-2893.2005.00661.x | Medline

[42]

Sablon E, Saphiro F..

Advances in Molecular Diagnosis of HBV infection and drug resistance..

Int J Med Sci. , 2 (2005), pp. 8-16

Medline